PharmaEssentia data show 55% of first-line BESREMi patients with polycythemia vera remain on treatment at two years
PHAR•PHAR•PHAR•PHAR•PharmaEssentia said real-world data showed more than half of polycythemia vera patients remained on first-line BESREMi treatment at two years, with greater persistence among younger patients.
PharmaEssentia will present six research posters on October 29 at the International Congress on Myeloproliferative Neoplasms, which runs October 29-30 in Brooklyn, New York. Real-world data showed more than half of polycythemia vera patients remained on first-line BESREMi at two years, with greater persistence among younger patients.
Japanese trial analyses linked faster BESREMi dose escalation to greater reductions in a disease-driving mutation, with similar blood count control. A Chinese real-world study found blood count responses improved over time, while reported adverse events were mild or moderate. Separate analyses highlighted limited treatment options in essential thrombocythemia and persistent thrombosis risk with hydroxyurea.
